UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?

Frontiers in oncology, 2020-01, Vol.9, p.1546-1546

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Nature communications, 2021-05, Vol.12 (1), p.2498-2498, Article 2498

2021

Link zum Volltext

Verfügbarkeit prüfen

Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report

EMBO molecular medicine, 2020-07, Vol.12 (7), p.e11756-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression

Vaccines (Basel), 2022-01, Vol.10 (1), p.78

2022

Link zum Volltext

Verfügbarkeit prüfen

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Cancer medicine (Malden, MA), 2018-09, Vol.7 (9), p.4339-4344

2018

Link zum Volltext

Verfügbarkeit prüfen

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer

Expert opinion on pharmacotherapy, 2016-11, Vol.17 (16), p.2179-2189

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study

Cancers, 2020-01, Vol.12 (2), p.327

2020

Link zum Volltext

Verfügbarkeit prüfen

De-escalation in low-risk, HER2-positive breast cancer

The lancet oncology, 2023-03, Vol.24 (3), p.200-201

2023

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study

ESMO open, 2020-01, Vol.5 (5), p.e000876-e000876, Article e000876

2020

Link zum Volltext

Verfügbarkeit prüfen

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer

ESMO open, 2020-10, Vol.5 (5), p.e000937-e000937, Article e000937

2020

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant ovarian suppression in premenopausal breast cancer

The New England journal of medicine, 2015-04, Vol.372 (17), p.1672

2015

Link zum Volltext

Verfügbarkeit prüfen

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions

World journal of clinical oncology, 2014-12, Vol.5 (5), p.990-1001

2014

Link zum Volltext

Verfügbarkeit prüfen

Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

Virchows Archiv : an international journal of pathology, 2023-03, Vol.482 (3), p.463-475

2023

Link zum Volltext

Verfügbarkeit prüfen

Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

Expert opinion on investigational drugs, 2015-03, Vol.24 (3), p.421-431

2015

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2024-01, Vol.403 (10421), p.31-43

2024

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Drug design, development and therapy, 2021-01, Vol.15, p.2711-2720

2021

Link zum Volltext

Verfügbarkeit prüfen

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2017-09, Vol.23 (17), p.5015-5023

2017

Link zum Volltext

Verfügbarkeit prüfen

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Expert opinion on pharmacotherapy, 2019-01, Vol.20 (1), p.5-9

2019

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

Virchows Archiv : an international journal of pathology, 2023-03, Vol.482 (3), p.477-477

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2871: Hypermetastatic stem-like cells from 'cancer of unknown primary' (CUP) model multi-organ dissemination and unveil liability to MEK inhibition

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2871-2871

2021

Link zum Volltext

Verfügbarkeit prüfen

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Clinical cancer research, 2015-04, Vol.21 (8), p.1869-1876

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

The New England journal of medicine, 2015-04, Vol.372 (17), p.1672-1673

2015

Link zum Volltext

Verfügbarkeit prüfen

Omission of axillary dissection after a positive sentinel lymph-node: implications in the multidisciplinary treatment of operable breast cancer

Cancer treatment reviews, 2016-07, Vol.48, p.1-7

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(51)
Female
(26)
Humans
(24)
Oncology
(20)
Animals
(18)
Breast Cancer
(16)
Chemotherapy
(12)
Breast Neoplasms - Drug Therapy
(11)
Tumors
(11)
Metastasis
(10)
Rats
(10)
Male
(9)
Aged
(8)
Antineoplastic Agents - Therapeutic Use
(8)
Middle Aged
(8)
Pharmacology & Pharmacy
(8)
Cancer
(7)
Metastases
(7)
Rats, Wistar
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study

De-escalation in low-risk, HER2-positive breast cancer

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer

Adjuvant ovarian suppression in premenopausal breast cancer

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions

Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

Abstract 2871: Hypermetastatic stem-like cells from 'cancer of unknown primary' (CUP) model multi-organ dissemination and unveil liability to MEK inhibition

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Omission of axillary dissection after a positive sentinel lymph-node: implications in the multidisciplinary treatment of operable breast cancer

Suchergebnisse filtern